Appeal No. 2000-1812
Application No. 08/432,483
administered to a mammal raise an antibody response against the mammal’s own
endogenous CETP. These peptides are described as being comprised of a helper T cell
epitope portion linked to a B cell epitope portion comprised of all or a portion of the
carboxyl terminal portion of human CETP protein.
Claim Interpretation
Claim 1 is directed to an isolated antigenic hybrid peptide comprising a T cell
epitope portion linked to a B cell epitope portion wherein the B cell epitope comprises six
to 26 consecutive amino acids of the carboxyl terminal 26 amino acids of human
cholesteryl ester transfer protein. This 26 amino acid sequence is defined in SEQ ID NO:
1 of the specification. Claim 2 is directed to the isolated antigenic hybrid peptide but
further provides that the T cell epitope portion is selected from a defined group which
includes tetanus toxoid, among other T cell epitopes. Claim 5 is directed to an isolated
antigenic hybrid peptide comprising the amino acid sequence of SEQ ID NO: 2. As noted
by the examiner (Answer, page 8) “[c]laim 5 is not limited to conjugates consisting of just
the 16 amino terminal residues of CETP." The use of the term comprising in claim 5
opens up the claim to read upon a peptide comprising the 16 mer but also containing
additional CETP residues. Claim 11 is directed to a method of elevating the ratio of
circulating HDL to circulating LDL, VLDL or total cholesterol in an animal or human by
administering to the animal or human an antigenic vaccine hybrid peptide of the type
claimed in claim 1. Claim 29 is directed to a method of treating atherosclerosis in a
5
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007